Research Library
Liraglutide research
6 articles to explore, with links to 9 original sources.
About Liraglutide
Liraglutide is a modified GLP-1 analogue used in research on incretin-receptor signaling.
Understand the science
How a stroke trial explored insulin resistance
Liraglutide is a peptide that activates the GLP-1 receptor. A 2026 analysis of the LAMP trial explored whether the association between liraglutide and recurrent stroke differed with participants’ starting insulin resistance.
3 sources (2025, 2026)
Explore study findings
What exercise and liraglutide changed in a weight-maintenance study
Liraglutide is a modified GLP-1 receptor agonist peptide. A 2026 analysis of the S-LiTE trial examined whether exercise, liraglutide or both changed measurements of blood vessel health after participants had already lost weight through a supervised program.
1 source (2026)
Why a five-week body composition study reported amounts and percentages
Liraglutide is a modified GLP-1 receptor agonist. A 2026 report from a small randomized study looked at how body composition changed during a short period, with special attention to the difference between the amount of lean tissue and its share of total body weight.
1 source (2026)
Check methods and identity
Why a type 1 diabetes study measured C-peptide
Liraglutide is a modified GLP-1 receptor agonist peptide. Its effects on blood glucose in type 2 diabetes led researchers to ask a narrower question in people with long-standing type 1 diabetes. Could the medicine preserve any insulin-making function that remained?
2 sources (2025, 2026)
What the ELAD trial measured in the brains of people with Alzheimer’s disease
Liraglutide is a peptide that activates the GLP-1 receptor and is approved for specific uses in diabetes and weight management, depending on the product. The ELAD trial studied it in people with mild to moderate Alzheimer’s disease, an investigated use.
3 sources (2025)
Interpret the evidence
What pediatric clinic records add to the liraglutide evidence
Liraglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. In 2026, investigators examined health records to see how blood sugar measures changed in young people with type 2 diabetes who received liraglutide in a clinical setting.
3 sources (2025, 2026)
